Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/chapter/10.1007/978-1-4614-0254-1_9, but it redirected us to https://link.springer.com/chapter/10.1007/978-1-4614-0254-1_9. The analysis below is for the second page.

Title[redir]:
Cancer Stem Cells, Models of Study and Implications of Therapy Resistance Mechanisms | SpringerLink
Description:
There is now compelling evidence for tumour initiating or cancer stem cells (CSCs) in human cancers. The current evidence of this CSC hypothesis, the CSC phenotype and methods of identification, culture and in vitro modelling will be presented, with an emphasis on...

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,473,390 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, pubmed, cancer, cas, stem, cells, cell, human, prostate, res, nature, identification, resistance, nat, chapter, sci, drug, rev, tumors, epithelial, research, med, characterization, natl, maitland, leukemia, biol, acute, mol, normal, therapy, tumour, tumor, tumorinitiating, proc, acad, oncol, breast, privacy, cookies, content, information, publish, mechanisms, frame, evidence, target, treatment, leukaemia,

Topics {✒️}

human colon-cancer-initiating cells prostate carcinoma-­initiating stem ovarian cancer-initiating cells cd44+alpha2beta1+ cell population cancer-stem-cell research vcap androgen-independent model prostate cancer-initiating cells acute lymphoblastic leukemia month download article/chapter htert-­immortalized primary nonmalignant human cell transformation cancer stem cells–perspectives human pancreatic cancer stem-cell leukemia tumor-initiating cells dna damage response hematopoietic stem cell hematopoietic stem cells progenitor cell population pluripotent stem cells tumor-initiating features oral cancer stem human prostate cancer multicellular tumor spheroids tumor stem cells privacy choices/manage cookies yorkshire cancer research human somatic cells prostate epithelial cells tumour-initiating cell inhibits growth microrna pathway plays adult human fibroblasts metastatic progenitor cells adult stem cells cancer stem cell primitive hematopoietic cell cancer stem cells leukaemia stem cells human renal carcinomas human aldehyde dehydrogenase stem cell programs mediate stem cell stem cell survival stem cell division stem cell states prostate cancer cells combined targeted treatment chronic myeloid leukaemia breast cancer cells

Questions {❓}

  • Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy?
  • Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality?
  • Jordan CT (2009) Cancer stem cells: controversial or just misunderstood?
  • Maitland NJ et al (2010) Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems?
  • Maitland NJ et al (2010) Prostate cancer stem cells: Do they have a basal or luminal phenotype?
  • Maitland NJ, Collins AT (2010) Cancer stem cells – a therapeutic target?
  • Wang Y, Armstrong SA (2008) Cancer: inappropriate expression of stem cell programs?

Schema {🗺️}

ScholarlyArticle:
      headline:Cancer Stem Cells, Models of Study and Implications of Therapy Resistance Mechanisms
      pageEnd:118
      pageStart:105
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4614-0254-1.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Human Cell Transformation
         isbn:
            978-1-4614-0254-1
            978-1-4614-0253-4
         type:Book
      publisher:
         name:Springer New York
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Fiona M. Frame
            affiliation:
                  name:University of York
                  address:
                     name:Department of Biology, YCR Cancer Research Unit, University of York, Heslington, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Norman J. Maitland
            affiliation:
                  name:University of York
                  address:
                     name:YCR Cancer Research Unit, Department of Biology, University of York, Heslington, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Stem Cell, Prostate Cancer, Androgen Receptor, Cancer Stem Cell, Luminal Cell
      description:There is now compelling evidence for tumour initiating or cancer stem cells (CSCs) in human cancers. The current evidence of this CSC hypothesis, the CSC phenotype and methods of identification, culture and in vitro modelling will be presented, with an emphasis on prostate cancer. Inherent in the CSC hypothesis is their dual role, as a tumour-initiating cell, and as a source of treatment-resistant cells; the mechanisms behind therapeutic resistance will be discussed. Such resistance is a consequence of the unique CSC phenotype, which differs from the differentiated progeny, which make up the bulk of a tumour. It seems that to target the whole tumour, employing traditional therapies to target bulk populations alongside targeted CSC-specific drugs, provides the best hope of lasting treatment or even cure.
      datePublished:2011
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Human Cell Transformation
      isbn:
         978-1-4614-0254-1
         978-1-4614-0253-4
Organization:
      name:Springer New York
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of York
      address:
         name:Department of Biology, YCR Cancer Research Unit, University of York, Heslington, UK
         type:PostalAddress
      name:University of York
      address:
         name:YCR Cancer Research Unit, Department of Biology, University of York, Heslington, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Fiona M. Frame
      affiliation:
            name:University of York
            address:
               name:Department of Biology, YCR Cancer Research Unit, University of York, Heslington, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Norman J. Maitland
      affiliation:
            name:University of York
            address:
               name:YCR Cancer Research Unit, Department of Biology, University of York, Heslington, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Biology, YCR Cancer Research Unit, University of York, Heslington, UK
      name:YCR Cancer Research Unit, Department of Biology, University of York, Heslington, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(426)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Pbgrd

5.43s.